The stock price of Immunic Inc (NASDAQ: IMUX) has dropped by -7.97 compared to previous close of 1.38. Despite this, the company has seen a fall of -2.31% in its stock price over the last five trading days. Proactive Investors reported 2024-05-08 that Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator vidofludimus calcium (IMU-838), during the first quarter of 2024. CEO Daniel Vitt highlighted progress in the company’s Phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and the twin Phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) for its “potentially groundbreaking” therapy vidofludimus calcium.
Is It Worth Investing in Immunic Inc (NASDAQ: IMUX) Right Now?
Moreover, the 36-month beta value for IMUX is 1.86. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMUX is 83.30M and currently, short sellers hold a 3.45% of that float. On May 09, 2024, IMUX’s average trading volume was 495.79K shares.
IMUX’s Market Performance
IMUX stock saw a decrease of -2.31% in the past week, with a monthly decline of -1.55% and a quarterly a decrease of 4.96%. The volatility ratio for the week is 6.63%, and the volatility levels for the last 30 days are 7.39% for Immunic Inc (IMUX).. The simple moving average for the past 20 days is -1.85% for IMUX’s stock, with a -7.97% simple moving average for the past 200 days.
Analysts’ Opinion of IMUX
Many brokerage firms have already submitted their reports for IMUX stocks, with SVB Leerink repeating the rating for IMUX by listing it as a “Mkt Perform.” The predicted price for IMUX in the upcoming period, according to SVB Leerink is $5 based on the research report published on October 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $26. The rating they have provided for IMUX stocks is “Buy” according to the report published on September 19th, 2022.
Aegis Capital gave a rating of “Buy” to IMUX, setting the target price at $55 in the report published on April 15th of the previous year.
IMUX Trading at -4.60% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.16% of loss for the given period.
Volatility was left at 7.39%, however, over the last 30 days, the volatility rate increased by 6.63%, as shares sank -8.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.63% lower at present.
During the last 5 trading sessions, IMUX fell by -2.31%, which changed the moving average for the period of 200-days by -46.41% in comparison to the 20-day moving average, which settled at $1.2880. In addition, Immunic Inc saw -15.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Whaley Glenn, who purchase 5,000 shares at the price of $1.75 back on May 15 ’23. After this action, Whaley Glenn now owns 25,510 shares of Immunic Inc, valued at $8,750 using the latest closing price.
Stock Fundamentals for IMUX
The total capital return value is set at -3.36. Equity return is now at value -112.05, with -91.94 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -53.09.
Currently, EBITDA for the company is -99.11 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.09.
Conclusion
To wrap up, the performance of Immunic Inc (IMUX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
